IL17 and IFN-gamma inhibition for the treatment of autoimmune inflammation
申请人:Leban Johann
公开号:US08592456B2
公开(公告)日:2013-11-26
The present invention relates to compounds of the general formula (I), and the pharmaceutically acceptable salt or solvate thereof, as anti-inflammatory and immunomodulatory agents.
本发明涉及一般式(I)的化合物及其药物可接受的盐或溶剂,作为抗炎和免疫调节剂。
US8354436B2
申请人:——
公开号:US8354436B2
公开(公告)日:2013-01-15
US8592456B2
申请人:——
公开号:US8592456B2
公开(公告)日:2013-11-26
[EN] IL17 AND IFN-GAMMA INHIBITION FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATION<br/>[FR] INHIBITION DE L'IL17 ET DE L'IFN-GAMMA DANS LE TRAITEMENT D'UNE INFLAMMATION AUTOIMMUNE
申请人:4SC DISCOVERY GMH
公开号:WO2012101261A1
公开(公告)日:2012-08-02
The present invention relates to compounds of the general formula (I), and the pharmaceutically acceptable salt or solvate thereof, as anti-inflammatory and immunomodulatory agents.
IL17 AND IFN-GAMMA INHIBITION FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATION
申请人:LEBAN Johann
公开号:US20120196861A1
公开(公告)日:2012-08-02
The present invention relates to compounds of the general formula (I), and the pharmaceutically acceptable salt or solvate thereof, as anti-inflammatory and immunomodulatory agents.